MedTrace Logo

Assessment of Exercise Response in Chronic Fatigue Syndrome / Myalgic Encephalomyelitis.

NCT03675087 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2025-03-10

No results posted yet for this study

Summary

This study evaluates the correlation between the 6-min walking test (6MWT) with gases measurement, and the peak cardiopulmonary exercise testing (CPET) using incremental cycling with gases and workload measurement, in order to determine if the 6MWT detects impairment in exercise tolerance and if it avoids the post-exertional malaise that the peak CPET causes on decreasing levels of physical activity, in participants affected by chronic fatigue syndrome/ myalgic encephalomyelitis (CFS/ME).

Physical activity level at baseline (usual activity, the parcipant will not be given any directions) will be recorded during 7 days, 24 hours/day. Afterwards, the 6MWT will be performed. After this test, the physical activity level will be collected again during 7 days, 24 hours/day. Peak CPET will be carried out 14 days after 6MWT to make sure that the basal levels are recovered, and finally, physical activity level will be collected again during 7 days, 24 hours/day.

Conditions

  • Fatigue Syndrome, Chronic

Sponsors & Collaborators

  • Hospital Universitario La Paz

    collaborator OTHER

  • Escuela Universitaria de Fisioterapia de la Once

    lead OTHER

Principal Investigators

  • Ana B Varas-de-la-Fuente, Chair · Escuela Universitaria de Fisioterapia de la Once

  • Susana García-Juez · Escuela Universitaria de Fisioterapia de la Once

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-27
Primary Completion
2025-07-31
Completion
2025-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03675087 on ClinicalTrials.gov